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Infection with human papillomaviruses is associated with a series of benign and malignant hyperproliferative
diseases that impose a heavy burden on human populations. A subgroup of mucosal human papillomavirus
types are associated with the majority of cervical cancers and a relevant fraction of vulvar, vaginal, anal, penile
and head and neck carcinomas. Human papillomaviruses mediate cell transformation by the expression of two
pleiotropic oncoproteins that alter major cellular regulatory pathways. However, these viruses are not complete
carcinogens, and further alterations within the infected cells and in their microenvironment are necessary
for tumor establishment and progression. Alterations in components of the extracellular matrix for instance,
matrix metalloproteinases and some of their regulators such as tissue inhibitors of metalloproteinases, have
been consistently reported in human papillomaviruses-associated diseases. Matrix metalloproteinases function
by remodeling the extracellular matrix and alterations in their expression levels and/or activity are associated
with pathological processes and clinical variables including local tumor invasion, metastasis, tumor relapse
and overall patient prognosis and survival. In this review we present a summarized discussion on the current
data concerning the impact of human papillomavirus infection on the activity and expression of extracellular
matrix components. We further comment on the possibility of targeting extracellular matrix molecules in
experimental treatment protocols.
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’ INTRODUCTION
Human papillomaviruses (HPVs) are small (B50 nm), non-
enveloped viruses with marked tropism for the stratified
epithelia of mucosa and the skin. The viral cycle is strictly
dependent on the epithelial differentiation program since the
availability of cellular factors expressed in different strata
of the epithelium play a role on viral gene expression and
genome amplification (see below). The genome of these viruses
is composed of a circular molecule of double-stranded DNA
of approximately 8 kbp packaged with cellular histones.
The viral DNA can be divided into three functional regions.
The long control region (LCR) or upstream-regulatory region
(URR) is a noncoding stretch of DNA that contains the viral
origin of replication and sites for binding viral and cellular
factors. The combination of viral and cellular proteins that
bind to this region regulates both viral genome replication
and gene transcription. In addition, HPVs exhibit two coding
regions. The early region (E) codifies the early genes that regu-
late viral DNA replication and gene expression (E1, E2, E7),
viral persistence (E5, E6 and E7), immune evasion (E5, E6 and
E7), inhibition of apoptosis (E6 and E7) and virion maturation
and release (E4). The late region (L) contains the genes that
codify the major (L1) and minor (L2) capsid proteins (1).
HPV infections are ubiquitous and are associated with
a series of hyperproliferative pathologies of epithelia and
mucosa as well as most cases of cervical cancer and genital
warts (2,3). To date, more than 200 HPV types have been
described (4). Almost 40 types exhibit particular tropism for
the mucosa of the anogenital region. HPV types from this
subgroup are classified as being of high or low oncogenic
risk, according to their association with cervical cancer.
While high-risk HPV types are associated with almost the
totality of cervical cancer cases, low-risk HPV types are the
cause of almost all anogenital warts and low-grade lesions
with little tendency to malignant progression. The most
prevalent high-risk HPVs are HPV16 and HPV18, while the
most common low-risk types are HPV6 and HPV11. In addi-
tion, studies conducted during the last two decades have
clearly shown that infections with specific high-risk HPV
types are etiologically related with a significant proportion of
vulvar, vaginal, anal, penile and head and neck carcinomas (5,6).
High-risk HPV types express two oncogenes, E6 and E7,
that collaborate to immortalize normal human keratino-
cytes in cell culture systems and are essential to maintain theDOI: 10.6061/clinics/2018/e551s
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transformed phenotype in vivo (7). The main role of these
proteins during the HPV cycle is to generate a cellular micro-
environment permissive for viral replication (8). This includes
the induction of DNA replication machinery, immune eva-
sion and downregulation of apoptosis (9-17). To achieve
this goal, E6 and E7 target critical cellular regulatory
pathways including those mastered by p53 and pRb,
respectively (18-20).
Despite the high impact of the expression of HPV proteins
on cellular homeostasis, these viruses are incomplete carcino-
gens. Therefore, further alterations in the cell as well as in
its microenvironment are necessary for tumor establishment
and progression. This process includes dysregulation of the
extracellular matrix (ECM). In some cases, alterations in the
levels and activity of defined ECM components have been
experimentally associated with the expression of specific
HPV proteins, suggesting the direct involvement of the
virus in the deregulation of these factors. Other studies,
mainly those conducted using clinical samples, have identi-
fied alterations in the levels of ECM molecules during the
progression of HPV-related diseases. However, in most
situations the direct involvement of viral proteins on these
alterations has not been addressed. In this review we discuss
the current state of knowledge concerning the impact of HPV
infection on the expression and function of components of
the ECM.
ECM alterations in HPV-associated anogenital
intraepithelial neoplasias
The natural history of cervical cancer development arises
from precursor lesions, called cervical intraepithelial neo-
plasias (CINs). CIN 1 and a subgroup of CIN 2 lesions are
classified as productive lesions, in which the viral cycle is
complete. On the other hand, a subgroup of CIN 2 and all
CIN 3 lesions are cervical cancer precursors. The develop-
ment of these lesions is mainly caused by persistent infection
with oncogenic HPV types. Productive lesions present low to
moderate histological alterations and spontaneously regress
in the period of 1 to 2 years. In the event of high-risk HPV
persistent infections, high-grade precancerous lesions (a sub-
group of CIN 2 and all CIN 3) may develop within 3 to 5 years.
Morphologically, CIN 3 (carcinoma in situ [CIS]) represents
a heterogeneous disease, and it can be considered a precur-
sor lesion to a more advanced, invasive cervical cancer (21).
HPV infection has been associated with several altera-
tions in tissue organization and architecture, including
dysregulation of matrix metalloproteinase (MMP) expres-
sion and activity. Additionally, alterations in different
molecules of the ECM can be observed in HPV-associated
CINs. The main alterations in ECM components in CIN
are summarized in Figure 1. For example, when MMP-2
expression was analyzed in cervical samples, the levels
of this protein were undetectable in normal cervix and
Figure 1 - An overview of the reported ECM alteration events in HPV-associated pathologies. A) HPV infections are strongly associated
with the development of skin and genital warts and cervical cancer precursor lesions. HPV gains access to the basal layer of the
epithelium through microwounds and initiates the infection. HPV-associated warts are characterized by nontransforming (or benign)
increased cell proliferation of the anogenital skin and mucosa due to productive viral infection. The epidermis of HPV-infected skin,
mucosa and genital warts may present papillomatosis, acanthosis (increased number of cell layers), hyperkeratosis and parakeratosis.
Warts frequently show elongated epithelial ridges roughly directed to the center of the wart and increased vascularization of
the bordering dermis. In warts and low-grade cervical intraepithelial neoplasias (CIN 1), the HPV genome is frequently found in
the episomal form. On the other hand, integration of the HPV genome and resulting higher expression of E6 and E7 oncogenes are
common features of high-grade CIN (2 and 3) and invasive cervical cancer. HPV-associated lesions are characterized by the presence
of keratinocytes with atypical morphology, called koilocytes, that exhibit (I) increased cell size and (II) eccentric and pyknotic
nuclei bordered by a perinuclear halo. B) The heatmap presented summarizes the reported alterations in ECM molecule expression
(either mRNA or protein levels) in cervical cancer precursor lesions and invasive carcinomas.
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low-grade lesions. In contrast, high-grade lesions and inva-
sive carcinomas showed high MMP-2 expression, suggesting
that MMP-2 may constitute an early marker for cervical cancer
progression. Additionally, these results suggest that upregu-
lated MMP-2 expression may be associated with the potential
risk of invasion and metastasis (22,23). MMP-2 is also called
gelatinase A and has fibronectin type II repeats in its catalytic
domain, which mediates collagen binding to this protease.
MMP-2 major function involves collagen type IV breakdown in
the basement membrane (24,25).
MMP-2 and its regulator tissue inhibitor of metallo-
proteinases type 2 (TIMP-2) are important determinants in
the behavior of invasive tumors and in their metastatic
potential. A previous study conducted with clinical samples
from patients with CIN or invasive squamous cell cervical
carcinoma (CC) showed that MMP-2 expression levels pre-
sented a positive correlation with CIN grade, and was
further increased after progression to invasive cancer. How-
ever, TIMP-2 expression presented no alterations when
normal tissues were compared to CIN 3 tissues (26). On the
other hand, our group has shown that HPV16 E7 expres-
sion is associated with a decrease in TIMP-2 expression and
function in primary keratinocytes (27). Zhou et al. (28) ana-
lyzed the expression of MMP-2, MMP-9, TIMP-1 and TIMP-
2 in normal cervix, CIN cervix samples and cervical cancer
samples using an immunohistochemistry (IHC) assay. Their
results suggest that overexpression of these ECM components
may play a key role in cervical cancer-associated lymph node
invasion and metastasis.
In an early study, Davidson et al. (29) analyzed the expres-
sion of MMP-9 in cervical squamous cell carcinoma and CIN
2-3 samples and observed that MMP-9 mRNA and protein
expression were elevated in both high-grade CIN and inva-
sive squamous cell carcinoma when compared with normal
samples. Therefore, MMP-9 was also suggested as a possible
early marker of cervical lesion progression. No et al. (30) also
detected a higher expression of MMP-9 in CIN 3 lesions than
that in CIN 1 and 2 lesions. In addition, our group has shown
that the expression of the MMP inhibitor (MMPI) reversion-
inducing protein cysteine-rich protein with kazal motifs
(RECK) is downregulated in high-grade CIN and cervical
cancer samples when compared with low-grade CIN and
control samples. In addition, previous data from our group
demonstrated that transduction with HPV16 E6 and E7
oncogenes correlates with reduced expression of the RECK
protein in organotypic cultures of primary keratinocytes. We
also observed increased MMP-2 and MMP-9 expression and
activity in this system (27). Altogether, these results suggest
that upregulation of MMP-2 and MMP-9 expression and
activity are associated with high-grade CIN. On the other
hand, the MMPI RECK exhibits reduced levels of expression
in these lesions (26-28,31). These results are summarized in
Figure 1B.
Recently, Valdivia et al. (32) analyzed the expression of
MMP-11 and MMP-12 in low- and high-grade squamous
lesions (LSIL and HSIL, respectively) and cervical carci-
nomas. These authors observed that samples with posi-
tive expression for MMP-11 were also positive for MMP-12,
and their expression increased according to lesion grade. In
addition, they showed that MMP-11 and MMP-12 proteins
accumulated mainly in the cytoplasm of transformed cells.
On the other hand, these proteins were not detected in normal
epithelia. These results indicate that MMP-11 and MMP-12
may be associated with the onset of cancer precursor lesions
and suggest that increased expression of these proteins can
be considered an early event during the development of
preneoplastic cervical lesions. The MMP-11 gene, which is also
called stromelysin-3 (ST-3), is located on chromosome 22q11.23
and has been identified in a breast cancer cDNA library. MMP-12,
also known as metalloelastase or macrophage elastase, is found
on chromosome 11q22.3 (25,32-34).
Alterations in other ECM components have also been
explored in the cervical tissue transformation context. Branca
et al. (35) have found that 67-kDa laminin receptor (LR67)
expression progressively increases with CIN grade. LR67 is
associated with CIN 2 to CIN 3 progression, and it can be
thought of as a marker of cellular proliferation in cervical
tissue (26). These authors have also shown that the combined
analysis of LR67 and vascular endothelial growth factor-C
(VEGF-C) may improve high-grade CIN clinical detection (35).
Moreover, analysis of the expression of sindecan-1 and
claudins (CLDNs) in CIN 1, 2, and 3 and CIS lesions dem-
onstrated that sindecan-1 and CLDNs 1, 4 and 7 expression
levels are similar among CIN 2 and 3, CIS and normal epithe-
lium. However, CLDN3 was not detectable in the squamous
epithelium (36).
HPV infection has also been linked to a relevant percen-
tage of lesions in other epithelia of the anogenital tract
including the vulva, vagina and anus. Vulvar, vaginal and
anal cancer precursor lesions are also denominated as vulvar
intraepithelial neoplasia (VIN), vaginal intraepithelial neo-
plasia (VAIN) and anal intraepithelial neoplasia (AIN),
respectively (37). Similar to what is observed in cervical
precursor lesions, VIN, VAIN and AIN also progress through
grades of epithelial transformation. Previous studies have
determined the HPV DNA prevalence in VAIN, VIN and
AIN on four continents using PCR assays. HPV6 and HPV11
were the most prevalent HPV types found in VIN 1 and AIN.
Moreover, HPV16 was detected in 75% of vulvar, vaginal
and anal HPV-positive carcinomas. The same study also
determined that HPV18 was detected in only 10% of the
evaluated samples (38). In another study, HPV16 or HPV18
were found in 76% of VIN 2-3, 64% of VAIN 2-3, 81% of AIN
2-3 and 42% of vulvar carcinoma samples. Additionally,
the same HPV types were observed in 58% of women under
56 years of age who were diagnosed with carcinoma of the
vulva (39).
Finally, a retrospective study analyzed the expression of
MMP-2, MMP-9, TIMP-1 and TIMP-2 by IHC in VIN 1, 2 and
3 samples and invasive vulvar carcinoma. The results from
this study suggested that overexpression of MMP-2, MMP-9
and TIMP-2 proteins may be related with the progression of
VIN to invasive carcinoma (40).
ECM composition in HPV-associated cancers
The carcinogenic process naturally culminates in the over-
coming of multiple ECM regulatory mechanisms in order
to promote tissue invasion of established tumors (41). The
dysregulation of ECM remodeling proteins is a common fea-
ture in the natural history of human cancers, resulting in
an overall collapse in normal ECM composition and main-
tenance (42,43). This event is a devastating consequence of
the imbalance between expression and activity of specific
proteases and their natural negative regulators, which leads
to an altered deposition-to-degradation ratio of several base-
ment membrane structural molecules.
Disruption of ECM remodeling regulation through imbal-
anced proteolysis has a major role in loss-of-tissue homeostasis
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and pathological processes such as cancer. In cancer, this event
can impact (I) tissue tension and (II) the release of chemotactic
fragments of ECM components that influence the local micro-
environment, as it favors (III) cell migration and recruitment
of stromal, endothelial and immune cells to the tumor vicinity.
The heterotypical association of cancer cells and other elements
observed in the tumor microenvironment, such as inflamma-
tory infiltrates, endothelial cells and tumor-associated fibro-
blasts, must also be explored in order to fully understand the
alterations in ECM remodeling resulting from this intricate
crosstalk (44).
Historically, the most investigated proteases present in this
crossroad are the MMPs. The activity of specific MMP types
such as MMP-2, MMP-9 and membrane type 1 (MT1)-MMP
is upregulated in most human cancers. These MMPs play a
central role in basement membrane breakdown and cell inva-
sion, as well as in neoangiogenesis and metastasis (25,45).
The excess of MMP activity generates topographical changes
in the tumor microenvironment by proteolysis-associated modi-
fications of the structural ECM scaffold. In fact, linearization,
thickening and/or degradation of specific collagen are com-
mon events observed in epithelial tissue areas adjacent to
tumor-associated blood vessels, where cancer cells invade.
MMP activity also regulates cellular migration and release
of ECM fragments with biological functions, such as growth
factors (42).
The crucial role of specific MMPs in the process of carcino-
genesis has set an objective task for researchers in the field to
explore the potential of MMPs as therapeutic targets (46).
However, the use of broad-spectrum, small-molecule MMPIs
offers no clinical advantages due to the dose-limiting side
effects (46,47). For example, some of the nonspecific MMP
inhibitors also downregulate the TNF-a converting enzyme
(TACE) and prevent the release of TNF-a receptor II
(TNF-RII), which contributes to the side effect of musculo-
skeletal pain (47-49). Nevertheless, novel and more specific
MMPIs and MMP cleavage-associated cytotoxic treatments
are being tested in clinical trials as potential cancer treatment
options (50-52).
Several authors have studied ECM alterations in both struc-
tural and remodeling molecules in invasive cervical cancer.
More specifically, alterations in the expression/activity of galectins,
collagens, proteoglycans, laminins, fibronectins, integrins and
proteases and their regulators were observed in both cervical
cancer samples and derived cell lines. Considering the current
review, we aim to assemble a more complete view of the
spectrum of ECM alterations in HPV-associated tumors,
mainly regarding cervical cancer.
MMPs in HPV-associated cancers
HPV16 seems to be associated with higher expression/
activity of specific MMPs during cervical cancer progression
(27,31,53,54). Indeed, the imbalance between the expression/
activity of proteases such as MMPs and their negative regu-
lators is a common feature in both cervical cancer samples
and derived cell lines (22,27,31,54-56).
Several authors have reported the upregulation of speci-
fic MMPs in samples of cervical carcinoma when com-
pared to control healthy tissue, including MMP-1, MMP-2,
MMP-3, MMP-7, MMP-9, MMP-10, MMP-11, MMP-12,
MMP-13, MMP-14 (MT1-MMP) and MMP-15 (22,27,31,54–56).
The main alterations in ECM components in cervical tumors
are summarized in Figure 1. Kaewprag et al. (54) analyzed the
ability of HPV16 and HPV18 oncoproteins to regulate the
expression of MMP-1, MMP-2, MMP-7, MMP-9, MMP-10,
MMP-11 and MMP-14 (MT1-MMP). These authors found a
positive correlation between the expression level of MMPs and
the cell invasion potential of C33A cells stably expressing
different HPV16 oncoproteins. Furthermore, this study detected
an upregulation of MMP-2 and MT1-MMP gene expression
when C33A cells expressed both HPV16 E6 and E7 oncopro-
teins, which correlated with increased cell invasion. Conversely,
silencing of HPV16 E6 and E7 expression by shRNA led to the
downregulation of MMP-2 and MT1-MMP expression. This
was paralleled by a reduction in the invasive potential of these
cells. Altogether, these observations suggest the direct effects of
HPV oncoproteins in the modulation of these MMP types.
Moreover, elevated MMP-2 and MT1-MMP protein levels
were observed in clinical samples of HPV16-positive invasive
cervical tumors when compared to CIN and normal cervical
tissues. The authors also observed that PEA3 and Sp1 binding
sites present on MMP-2 and MT1-MMP promoters were essen-
tial for the transactivation activity mediated by HPV16 E6 and
E7. MT1-MMP (or MMP-14) functions include ECM remodel-
ing through proteolysis of collagen I, II, and III, fibrin, fibro-
nectin, laminin-1, laminin-5, and vitronectin (25).
Even though MMP proteolytic network alterations are com-
mon during the progression of cervical cancer, only upregula-
tion of the expression/activity of MMP-2 (gelatinase A) and/
or MMP-9 (gelatinase B) seems to be indicative of a poor pro-
gnosis in cervical cancer patients (22,57,58). In fact, others have
observed a correlation between MMP-2 and MMP-9 transcript
levels and cervical tumor invasion potential (22,55,56,59). Our
group has shown that SiHa and CaSki HPV-positive cervical
cancer-derived cell lines present higher levels of MMP-2, MT1-
MMP, and TIMP-2 than the C33A HPV-negative cell line (53).
Moreover, we demonstrated an association between HPV16
E6 and E7 expression, upregulation of MMP-2 and MMP-9
mRNA and decreased levels of their natural negative regulators
RECK and TIMP-2 mRNA in primary keratinocytes grown in
organotypic cultures (27). Finally, we analyzed RECK and
MMP-9 expression levels in clinical samples from patients
diagnosed with cervical cancer and observed (I) downregu-
lated RECK protein expression and (II) upregulated MMP-9
protein expression in cervical cancer when compared to
CIN 1 or normal cervical tissue (27,31). Interestingly, MMP-2
is constitutively expressed in several cell types, and the
accumulation of its active form depends on activation by
MT1-MMP, while specific cytokines can operate under
MMP-9 transcription regulation (60,61).
Branca et al. (26) observed a strong expression of MT1-MMP
in paraffin-embedded invasive cervical cancer samples
when compared to normal cervical tissues. This study also
showed that all cervical cancer-derived cell lines analyzed
(CaSki, C-4II, HT-3, ME-180, MS751, and HeLa) expressed
high levels of MT1-MMP and MMP-2. On the other hand,
Vazquez-Ortiz et al. (56) observed an upregulation of MMP-
10, MMP-11 and MMP-12 and a downregulation of MMP-13
in cervical cancer samples when compared to HSIL samples
using cDNA expression arrays. Additionally, it has been
observed that keratinocytes expressing E7 from high-risk
mucosal and cutaneous HPV types exhibit upregulated
expression of MT1-MMP (62).
Moreover, another study analyzed both protein levels and
proteolytic activity of 9 MMPs (MMP-1, MMP-2, MMP-3,
MMP-7, MMP-8, MMP-9, MMP-13, MMP-14, and MMP-15)
and TIMP-1, TIMP-2, and TIMP-3 in normal cervical tissue
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and LSIL, HSIL and cervical cancer clinical samples using
IHC assays and gelatin zymography. The authors observed an
increase in the protein levels of MMP-2 and MMP-9 in 13%,
80% and 90% of LSIL, HSIL and cervical cancer samples,
respectively (22). MMP-9 specific activity and/or MMP-2 active
protein levels were (I) increased in HSIL and cervical cancers
when compared to normal control tissues (II) and correlated
with increased lymph node metastasis and cancer relapse
(22,63). Finally, patients with early stages of cervical cancer
showed higher MMP-9 expression and experienced a decreased
recurrence-free survival after standard treatment (64).
Other ECMmolecules altered in HPV-associated cancer
The differential expression of specific modulators of ECM
protease activity plays a central role in tumor microenviron-
ment remodeling. These positive and negative modulators
present an intricate interplay that impacts both their expres-
sion and function in HPV-associated tumors (27,31,53,54).
Indeed, the protein levels of a disintegrin and metallo-
proteinase 17 (ADAM17), amphiregulin (AREG), ECM metallo-
proteinase inducer (EMMPRIN), and MMP were increased
in cervical carcinoma clinical samples when compared with
normal adjacent cervical tissues. Moreover, strong ADAM17,
AREG, and EMMPRIN protein expression was associated with
several poor prognosis parameters, including the presence of
lymph node metastasis and advanced tumor stage (65). One of
the mechanisms underlying the downregulation of TIMPs in
cervical cancer might be through the function of EMMPRIN.
Xu et al. (66) showed that exogenous expression of EMMPRIN
downregulated TIMP-1 protein in HPV-positive cervical cancer-
derived cell lines. These authors have also analyzed EMMPRIN
downregulation using iRNA and observed an increase in
TIMP-1 protein levels in the same cell lines.
Different types of collagens, including collagen types I,
II, III, V, and IX may show increased deposition in the tumor
microenvironment (42). Decreased expression or lack of
collagen IV is an independent predictive factor for cervical
lymph node invasion in patients with early stage cervical
carcinoma (67,68). Moreover, increased protein levels of
collagen XVII have been reported in cervical cancer clinical
samples and were associated with increased local tumor
spread. Additionally, this study showed that the COL17A1
gene was hypomethylated in cervical cancer clinical samples (69).
Syndecan 1, a transmembrane heparan sulfate cell surface
proteoglycan that is highly expressed in the normal cervical
epithelium (except for the basal cell layer), presents a marked
downregulation in invasive cervical carcinomas when
compared with CIN samples (36,70,71). Similar to what has
been shown for collagen IV, Numa et al. (70) showed that
decreased or absent syndecan 1 expression presents an
inverse correlation with cervical lymph node invasion but
not with overall prognosis in cervical cancer patients. In oppo-
sition to these results, it was reported that strong syndecan 1
cytoplasmic expression (without alterations in gene copy
number) correlates with improved survival and represents
an independent prognostic factor for patients diagnosed with
cervical carcinoma (72).
CLDNs and occludins are families of proteins associated
with the establishment of tight junctions and epithelial cell
polarity and intercellular permeability. Expression levels of
CLDN type 1, 2, 4 and 7 proteins were upregulated in HSIL
lesions and in invasive cervical tumors when compared with
normal cervical tissues (36,73). On the other hand, occludin is
expressed in the basal cell layer of normal cervical tissues,
and its protein level is decreased in invasive cervical carcino-
mas when compared with CIN samples. This study indicated
that alterations in cell adhesion and ECM structure are a
common early feature in cervical cancer progression (73).
The expression of the 67-kd high-affinity laminin–binding
protein (67LR) was increased in both CIN and cervical cancer
samples when compared with normal cervical tissues (26,74).
However, the latter study did not observe a significant capa-
bility 67LR to predict either (I) high-risk HPV infection clear-
ance in CIN after treatment or (II) survival in cervical cancer
patients (26).
Versican, an ECM proteoglycan, was evaluated in cervi-
cal cancer samples by IHC and in situ hybridization.
The expression of high levels of versican in tumor stromal
myofibroblasts was associated with (I) a lower frequency
of tumor-infiltrating CD8-positive T cells, (II) increased
tumor parametrial invasion and infiltration depth (III) and
no change in cervical cancer survival (75). Interestingly, the
beta-galactoside-binding protein galectin-1 was more expres-
sed in tumor-adjacent stromal cells when compared with
normal cervical tissue-associated stroma (76). Moreover,
a higher expression level of galectin-1 was associated with
increased local tumor relapse and poor cancer-specific sur-
vival in patients with stage I-II cervical tumors after radiation
treatment, although it could not predict distant metastasis (77).
In 2015, a new study presented more results on ECM changes
in cervical cancer clinical samples when compared with
normal cervical tissues obtained from hysterectomy (78).
All samples were previously verified for the presence of
HPV DNA by nested PCR (79). Formalin-fixed cervical
tissues were prepared for tissue microarray (TMA) and
analyzed through IHC for 25 different ECM molecules,
including laminin-1 and laminin-5, a-smooth muscle actin
(aSMA) and fibronectin. Laminin-1 (3.8-fold) and aSMA
(5.2-fold) proteins presented increased expression, mainly in
cervical tumor-surrounding stroma when compared with
normal cervical stroma. Moreover, tumor cells and both tumor
and normal tissue-associated fibroblasts were collected from
fresh cervical tissue and cultured in order to analyze the secre-
tion of ECM elements. In summary, (I) tumor cells mainly
expressed integrin a6b4 laminin receptors and (II) tumor-
associated fibroblasts showed higher levels of laminin-a1
and laminin-b1 and lower levels of laminin-5, fibronectin,
collagen III, TIMP-1 and the hyaluronan (HA) receptor CD44
when compared with normal fibroblasts (78). Finally, it has
been shown that MMP-7 and MMP-9 expression correlate
with CD44 expression in skin cancer cells (80,81).
The data discussed above show that alterations in the ECM
composition and function are common in HPV-associated
lesions and cancers. Altogether, these alterations highlight
the complex molecular pathways that lead from initial infec-
tion to disease. For instance, the analysis of the impact
of HPV on components of the MMP family that have been
addressed by studies from different groups around the world
have produced a plethora of data that could be used for
disease diagnosis and for the identification of targets for
therapy. The data summarized here also show that in regard
to the mechanisms by which HPV modulates MMP expres-
sion and activity, there is still much to learn. Finally, ECM
alterations may impact the HPV-infected tissue microenviron-
ment, affecting the recruitment of inflammatory infiltrates, altering
the fate of different cell populations present in the tumor and,
ultimately, determining the disease progression and prognosis.
5
CLINICS 2018;73(suppl 1):e551s HPV and the extracellular matrix
Herbster S et al.
Therefore, further studies are necessary to understand how
HPV proteins affect the dynamic ECM balance in associated
pathologies. This will help us to better understand the genesis
of the disease and define more suitable clinical interventions.
Importantly, a great majority of the ECM alterations described
in this review have also been observed in HPV-independent
tumors. Therefore, understanding the virus-mediated molecu-
lar events leading to ECM disturbance may prove of value for
understanding the basic mechanisms of carcinogenesis and the
development of more general antitumor approaches.
’ ACKNOWLEDGMENTS
This research was supported by grants from FAPESP (2008/57889-1;
2013/27006-9) (CNPq 573799/2008-3) and CAPES (1680367).
’ AUTHOR CONTRIBUTIONS
Herbster S prepared the text describing ECM alterations in HPV-associated
tumors. Paladino A prepared the text describing the general characteristics of
HPV and the effect of the virus on ECM alterations present in precursor
lesions and prepared the illustration in Figure 1. Freitas S assisted in the
preparation of text describing the general characteristics of HPV and the
effect of the virus on ECM alterations present in precursor lesions. Boccardo
E prepared, revised and corrected all the text.
’ REFERENCES
1. Doorbar J, Quint W, Banks L, Bravo IG, Stoler M, Broker TR, et al.
The biology and life-cycle of human papillomaviruses. Vaccine. 2012;
30(Suppl 5):F55-70, http://dx.doi.org/10.1016/j.vaccine.2012.06.083.
2. International Agency for Research on Cancer. Human Papillomaviruses,
vol. 90; 2007 [Internet]. IARC Monographs on the evaluation of carcino-
genic risks to humans. Available from: http://monographs.iarc.fr/ENG/
Monographs/vol90/mono90-6.pdf%5Cnhttp://monographs.iarc.fr/ENG/
Monographs/vol100B/mono100B-11.pdf.
3. International Agency for Research on Cancer. Human Papillomaviruses,
vol. 100B, 2012 [Internet]. IARC Monographs on the evaluation of carcino-
genic risks to humans. Available from: http://monographs.iarc.fr/ENG/
Monographs/vol100B/index.php.
4. PaVE: Papillomavirus Episteme [access in 15 december 2017]. Available
from: http://pave.niaid.nih.gov/.
5. Tota JE, Chevarie-Davis M, Richardson LA, Devries M, Franco EL. Epide-
miology and burden of HPV infection and related diseases: implications
for prevention strategies. Prev Med. 2011;53(Suppl 1):S12-21, http://dx.
doi.org/10.1016/j.ypmed.2011.08.017.
6. Serrano B, Brotons M, Bosch FX, Bruni L. Epidemiology and burden of
HPV-related disease. Best Pract Res Clin Obstet Gynaecol. 2018;47(1):
14-26, http://dx.doi.org/10.1016/j.bpobgyn.2017.08.006.
7. Goodwin EC, DiMaio D. Repression of human papillomavirus oncogenes
in HeLa cervical carcinoma cells causes the orderly reactivation of dormant
tumor suppressor pathways. Proc Natl Acad Sci U S A. 2000;97(23):12513-8,
http://dx.doi.org/10.1073/pnas.97.23.12513.
8. Banerjee NS, Wang HK, Broker TR, Chow LT. Human papillomavirus
(HPV) E7 induces prolonged G2 following S phase reentry in differentiated
human keratinocytes. J Biol Chem. 2011;286(17):15473-82, http://dx.doi.
org/10.1074/jbc.M110.197574.
9. Dyson N, Howley PM, Münger K, Harlow E. The human papilloma virus-16
E7 oncoprotein is able to bind to the retinoblastoma gene product. Science.
1989;243(4893):934-7, http://dx.doi.org/10.1126/science.2537532.
10. Barbosa MS, Edmonds C, Fisher C, Schiller JT, Lowy DR, Vousden KH.
The region of the HPV E7 oncoprotein homologous to adenovirus E1a and
Sv40 large T antigen contains separate domains for Rb binding and casein
kinase II phosphorylation. EMBO J. 1990;9(1):153-60, http://dx.doi.org/
10.1002/j.1460-2075.1990.tb08091.x.
11. Klingelhutz AJ, Foster SA, McDougall JK. Telomerase activation by the E6
gene product of human papillomavirus type 16. Nature. 1996;380(6569):
79-82, http://dx.doi.org/10.1038/380079a0.
12. Brehm A, Nielsen SJ, Miska EA, McCance DJ, Reid JL, Bannister AJ, et al.
The E7 oncoprotein associates with Mi2 and histone deacetylase activity
to promote cell growth. EMBO J. 1999;18(9):2449-58, http://dx.doi.org/
10.1093/emboj/18.9.2449.
13. Patel D, Huang SM, Baglia LA, McCance DJ. The E6 protein of human
papillomavirus type 16 binds to and inhibits co-activation by CBP and p300.
EMBO J. 1999;18(18):5061-72, http://dx.doi.org/10.1093/emboj/18.18.5061.
14. Helt AM, Galloway DA. Destabilization of the retinoblastoma tumor
suppressor by human papillomavirus type 16 E7 is not sufficient to
overcome cell cycle arrest in human keratinocytes. J Virol. 2001;75(15):
6737-47, http://dx.doi.org/10.1128/JVI.75.15.6737-6747.2001.
15. Cho NH, Kim YT, Kim JW. Alteration of cell cycle in cervical tumor
associated with human papillomavirus: cyclin-dependent kinase inhibitors.
Yonsei Med J. 2002;43(6):722-8, http://dx.doi.org/10.3349/ymj.2002.43.6.722.
16. Longworth MS, Laimins LA. The binding of histone deacetylases and the
integrity of zinc finger-like motifs of the E7 protein are essential for the life
cycle of human papillomavirus type 31. J Virol. 2004;78(7):3533-41,
http://dx.doi.org/10.1128/JVI.78.7.3533-3541.2004.
17. Pim D, Banks L. Interaction of viral oncoproteins with cellular target
molecules: infection with high-risk vs low-risk human papillomaviruses.
APMIS.2010;118(6-7):471-93, http://dx.doi.org/10.1111/j.1600-0463.2010.
02618.x.
18. Crook T, Tidy JA, Vousden KH. Degradation of p53 can be targeted by
HPV E6 sequences distinct from those required for p53 binding and trans-
activation. Cell. 1991;67(3):547-56, http://dx.doi.org/10.1016/0092-8674(91)
90529-8.
19. Lechner MS, Mack DH, Finicle AB, Crook T, Vousden KH, Laimins
LA. Human papillomavirus E6 proteins bind p53 in vivo and abrogate
p53-mediated repression of transcription. EMBO J. 1992;11(8):3045-52,
http://dx.doi.org/10.1002/j.1460-2075.1992.tb05375.x.
20. Scheffner M, Huibregtse JM, Vierstra RD, Howley PM. The HPV-16
E6 and E6-AP complex functions as a ubiquitin-protein ligase in the
ubiquitination of p53. Cell. 1993;75(3):495-505, http://dx.doi.org/10.1016/
0092-8674(93)90384-3.
21. Steenbergen RD, Snijders PJ, Heideman DA, Meijer CJ. Clinical implica-
tions of (epi)genetic changes in HPV-induced cervical precancerous lesions.
Nat Rev Cancer. 2014;14(6):395-405, http://dx.doi.org/10.1038/nrc3728.
22. Sheu BC, Lien HC, Ho HN, Lin HH, Chow SN, Huang SC, et al. Increased
expression and activation of gelatinolytic matrix metalloproteinases is
associated with the progression and recurrence of human cervical cancer.
Cancer Res. 2003;63(19):6537-42.
23. Nasr M, Ayyad SB, El-Lamie IK, Mikhail MY. Expression of matrix
metalloproteinase-2 in preinvasive and invasive carcinoma of the uterine
cervix. Eur J Gynaecol Oncol. 2005;26(2):199-202.
24. Brummer O, Böhmer G, Hollwitz B, Flemming P, Petry KU, Kühnle H.
MMP-1 and MMP-2 in the cervix uteri in different steps of malignant
transformation—an immunohistochemical study. Gynecol Oncol. 2002;
84(2):222-7, http://dx.doi.org/10.1006/gyno.2001.6413.
25. Lu P, Takai K, Weaver VM, Werb Z. Extracellular matrix degradation and
remodeling in development and disease. Cold Spring Harb Perspect Biol.
2011;3(12), doi: http://dx.doi.org/10.1101/cshperspect.a005058.
26. Branca M, Ciotti M, Giorgi C, Santini D, Di Bonito L, Costa S, et al. Matrix
metalloproteinase-2 (MMP-2) and its tissue inhibitor (TIMP-2) are prog-
nostic factors in cervical cancer, related to invasive disease but not to high-
risk human papillomavirus (HPV) or virus persistence after treatment of
CIN. Anticancer Res. 2006;26(2B):1543-56.
27. Cardeal LB, Boccardo E, Termini L, Rabachini T, Andreoli MA, di Loreto
C, et al. HPV16 oncoproteins induce MMPs/RECK-TIMP-2 imbalance in
primary keratinocytes: possible implications in cervical carcinogenesis.
PLoS One. 2012;7(3):e33585, http://dx.doi.org/10.1371/journal.pone.0033585.
28. Zhou CY, Yao JF, Chen XD. Expression of matrix metalloproteinase-2, 9
and their inhibitor-TIMP 1,2 in human squamous cell carcinoma of uterine
cervix. Ai Zheng. 2002;21(7):735-9.
29. Davidson B, Goldberg I, Kopolovic J, Lerner-Geva L, Gotlieb WH, Weis B,
et al. Expression of matrix metalloproteinase-9 in squamous cell carcinoma
of the uterine cervix-clinicopathologic study using immunohistochemistry
and mRNA in situ hybridization. Gynecol Oncol. 1999;72(3):380-6, http://
dx.doi.org/10.1006/gyno.1998.5285.
30. No JH, Jo H, Kim SH, Park IA, Kang D, Lee CH, et al. Expression of
MMP-2, MMP-9, and urokinase-type plasminogen activator in cervical
intraepithelial neoplasia. Ann N Y Acad Sci. 2009;1171:100-4, http://dx.
doi.org/10.1111/j.1749-6632.2009.04898.x.
31. Discacciati MG, Gimenes F, Pennacchi PC, Faião-Flores F, Zeferino LC,
Derchain SM, et al. MMP-9/RECK Imbalance: A Mechanism Associated
with High-Grade Cervical Lesions and Genital Infection by Human
Papillomavirus and Chlamydia trachomatis. Cancer Epidemiol Biomarkers
Prev. 2015;24(10):1539-47, http://dx.doi.org/10.1158/1055-9965.EPI-15-0420.
32. Valdivia A, Peralta R, Matute-González M, García Cebada JM, Casasola I,
Jiménez-Medrano C, et al. Co-expression of metalloproteinases 11 and
12 in cervical scrapes cells from cervical precursor lesions. Int J Clin Exp
Pathol. 2011;4(7):674-82.
33. Anglard P, Melot T, Guérin E, Thomas G, Basset P. Structure and promoter
characterization of the human stromelysin-3 gene. J Biol Chem. 1995;
270(35):20337-44, http://dx.doi.org/10.1074/jbc.270.35.20337.
34. Folgueras AR, Pendás AM, Sánchez LM, López-Otín C. Matrix metallo-
proteinases in cancer: from new functions to improved inhibition strategies.
Int J Dev Biol. 2004;48(5-6):411-24, http://dx.doi.org/10.1387/ijdb.041811af.
35. Branca M, Ciotti M, Giorgi C, Santini D, Di Bonito L, Costa S, et al. Pre-
dicting high-risk human papillomavirus infection, progression of cervical
intraepithelial neoplasia, and prognosis of cervical cancer with a panel of
13 biomarkers tested in multivariate modeling. Int J Gynecol Pathol.
2008;27(2):265-73.
6
HPV and the extracellular matrix
Herbster S et al.
CLINICS 2018;73(suppl 1):e551s
36. Sobel G, Szabó I, Páska C, Kiss A, Kovalszky I, Kádár A, et al. Changes of
cell adhesion and extracellular matrix (ECM) components in cervical
intraepithelial neoplasia. Pathol Oncol Res. 2005;11(1):26-31, http://dx.
doi.org/10.1007/BF03032402.
37. Zbar AP, Fenger C, Efron J, Beer-Gabel M, Wexner SD. The pathology and
molecular biology of anal intraepithelial neoplasia: comparisons with
cervical and vulvar intraepithelial carcinoma. Int J Colorectal Dis. 2002;
17(4):203-15, http://dx.doi.org/10.1007/s00384-001-0369-0.
38. De Vuyst H, Clifford GM, Nascimento MC, Madeleine MM, Franceschi S.
Prevalence and type distribution of human papillomavirus in carcinoma
and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis.
Int J Cancer. 2009;124(7):1626-36, http://dx.doi.org/10.1002/ijc.24116.
39. Hampl M, Sarajuuri H, Wentzensen N, Bender HG, Kueppers V. Effect
of human papillomavirus vaccines on vulvar, vaginal, and anal intra-
epithelial lesions and vulvar cancer. Obstet Gynecol. 2006;108(6):1361-8,
http://dx.doi.org/10.1097/01.AOG.0000245786.86267.80.
40. Määttä M, Santala M, Soini Y, Turpeenniemi-Hujanen T, Talvensaari-Mattila
A. Increased matrix metalloproteinases 2 and 9 and tissue inhibitor of matrix
metalloproteinase 2 expression is associated with progression from vulvar
intraepithelial neoplasia to invasive carcinoma. Acta Obstet Gynecol Scand.
2010;89(3):380-4, http://dx.doi.org/10.3109/00016340903555990.
41. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell.
2011;144(5):646-74, http://dx.doi.org/10.1016/j.cell.2011.02.013.
42. Egeblad M, Nakasone ES, Werb Z. Tumors as organs: complex tissues that
interface with the entire organism. Dev Cell. 2010;18(6):884-901, http://
dx.doi.org/10.1016/j.devcel.2010.05.012.
43. Muschler J, Streuli CH. Cell-matrix interactions in mammary gland
development and breast cancer. Cold Spring Harb Perspect Biol. 2010;
2(10):a003202, http://dx.doi.org/10.1101/cshperspect.a003202.
44. Mott JD, Werb Z. Regulation of matrix biology by matrix metalloprotei-
nases. Curr Opin Cell Biol. 2004;16(5):558-64, http://dx.doi.org/10.1016/
j.ceb.2004.07.010.
45. Kessenbrock K, Plaks V, Werb Z. Matrix metalloproteinases: regulators of
the tumor microenvironment. Cell. 2010;141(1):52-67, http://dx.doi.org/
10.1016/j.cell.2010.03.015.
46. Coussens LM, Fingleton B, Matrisian LM. Matrix metalloproteinase inhi-
bitors and cancer: trials and tribulations. Science. 2002;295(5564):2387-92,
http://dx.doi.org/10.1126/science.1067100.
47. Pavlaki M, Zucker S. Matrix metalloproteinase inhibitors (MMPIs): the
beginning of phase I or the termination of phase III clinical trials. Cancer
Metastasis Rev. 2003;22(2-3):177-203, http://dx.doi.org/10.1023/A:1023
047431869.
48. Nelson AR, Fingleton B, Rothenberg ML, Matrisian LM. Matrix metallo-
proteinases: biologic activity and clinical implications. J Clin Oncol. 2000;
18(5):1135-49, http://dx.doi.org/10.1200/JCO.2000.18.5.1135.
49. Steward WP, Thomas AL. Marimastat: the clinical development of a
matrix metalloproteinase inhibitor. Expert Opin Investig Drugs. 2000;9(12):
2913-22, http://dx.doi.org/10.1517/13543784.9.12.2913.
50. Fingleton B. MMPs as therapeutic targets--still a viable option? Semin Cell
Dev Biol. 2008;19(1):61-8, http://dx.doi.org/10.1016/j.semcdb.2007.06.006.
51. Sela-Passwell N, Trahtenherts A, Krüger A, Sagi I. New opportunities in drug
design of metalloproteinase inhibitors: combination between structure-function
experimental approaches and systems biology. Expert Opin Drug Discov.
2011;6(5):527-42, http://dx.doi.org/10.1517/17460441.2011.560936.
52. Dufour A, Overall CM. Missing the target: matrix metalloproteinase
antitargets in inflammation and cancer. Trends Pharmacol Sci. 2013;34(4):
233-42, http://dx.doi.org/10.1016/j.tips.2013.02.004.
53. da Silva Cardeal LB, Brohem CA, Corrêa TC, Winnischofer SM, Nakano F,
Boccardo E, et al. Higher expression and activity of metalloproteinases in
human cervical carcinoma cell lines is associated with HPV presence.
Biochem Cell Biol. 2006;84(5):713-9, http://dx.doi.org/10.1139/o06-084.
54. Kaewprag J, Umnajvijit W, Ngamkham J, Ponglikitmongkol M. HPV16
oncoproteins promote cervical cancer invasiveness by upregulating specific
matrix metalloproteinases. PLoS One. 2013;8(8):e71611, http://dx.doi.org/
10.1371/journal.pone.0071611.
55. Gilles C, Polette M, Piette J, Munaut C, Thompson EW, Birembaut P, et al.
High level of MT-MMP expression is associated with invasiveness of
cervical cancer cells. Int J Cancer. 1996;65(2):209-13, http://dx.doi.org/
10.1002/(SICI)1097-0215(19960117)65:2o209::AID-IJC1443.0.CO;2-8.
56. Vazquez-Ortiz G, Pina-Sanchez P, Vazquez K, Duenas A, Taja L, Mendoza
P, et al. Overexpression of cathepsin F, matrix metalloproteinases 11 and
12 in cervical cancer. BMC Cancer. 2005;5:68, http://dx.doi.org/10.1186/
1471-2407-5-68.
57. Rauvala M, Aglund K, Puistola U, Turpeenniemi-Hujanen T, Horvath G,
Willén R, et al. Matrix metalloproteinases-2 and -9 in cervical cancer:
different roles in tumor progression. Int J Gynecol Cancer. 2006;16(3):1297-
302, http://dx.doi.org/10.1111/j.1525-1438.2006.00448.x.
58. Libra M, Scalisi A, Vella N, Clementi S, Sorio R, Stivala F, et al. Uterine
cervical carcinoma: role of matrix metalloproteinases (review). Int J Oncol.
2009;34(4):897-903, http://dx.doi.org/10.3892/ijo_00000215.
59. Kato Y, Yamashita T, Ishikawa M. Relationship between expression of
matrix metalloproteinase-2 and matrix metalloproteinase-9 and invasion
ability of cervical cancer cells. Oncol Rep. 2002;9(3):565-9.
60. Mitra A, Chakrabarti J, Chattopadhyay N, Chatterjee A. Membrane-
associated MMP-2 in human cervical cancer. J Environ Pathol Toxicol
Oncol. 2003;22(2):93-100.
61. Clark IM, Swingler TE, Sampieri CL, Edwards DR. The regulation of
matrix metalloproteinases and their inhibitors. Int J Biochem Cell Biol.
2008;40(6-7):1362-78, http://dx.doi.org/10.1016/j.biocel.2007.12.006.
62. Smola-Hess S, Pahne J, Mauch C, Zigrino P, Smola H, Pfister HJ. Expression of
membrane type 1 matrix metalloproteinase in papillomavirus-positive cells:
role of the human papillomavirus (HPV) 16 and HPV8 E7 gene products.
J Gen Virol. 2005;86(Pt 5):1291-6, http://dx.doi.org/10.1099/vir.0.80551-0.
63. Wang PH, Ko JL, Tsai HT, Yang SF, Han CP, Lin LY, et al. Clinical signi-
ficance of matrix metalloproteinase-2 in cancer of uterine cervix: a semi-
quantitative study of immunoreactivities using tissue array. Gynecol
Oncol.2008;108(3):533-42, http://dx.doi.org/10.1016/j.ygyno.2007.11.018.
64. Talvensaari-Mattila A, Turpeenniemi-Hujanen T. Matrix metalloprotei-
nase 9 in the uterine cervix during tumor progression. Int J Gynaecol
Obstet. 2006;92(1):83-4, http://dx.doi.org/10.1016/j.ijgo.2005.08.021.
65. Xu Q, Ying M, Chen G, Lin A, Xie Y, Ohara N, et al. ADAM17 is asso-
ciated with EMMPRIN and predicts poor prognosis in patients with
uterine cervical carcinoma. Tumour Biol. 2014;35(8):7575-86, http://dx.
doi.org/10.1007/s13277-014-1990-1.
66. Xu Q, Cao X, Pan J, Ye Y, Xie Y, Ohara N, et al. Extracellular matrix
metalloproteinase inducer (EMMPRIN) remodels the extracellular matrix
through enhancing matrix metalloproteinases (MMPs) and inhibiting
tissue inhibitors of MMPs expression in HPV-positive cervical cancer cells.
Eur J Gynaecol Oncol. 2015;36(5):539-45.
67. Bremer GL, Tiebosch AT, van der Putten HW, de Haan J, Arends JW.
Basement membranes in cervical cancer: relationship to pelvic lymph
node metastasis and prognosis. Gynecol Oncol. 1995;57(3):351-5, http://
dx.doi.org/10.1006/gyno.1995.1154.
68. Smrkolj S, Erzen M, Rakar S. Prognostic significance of topoisomerase II
alpha and collagen IV immunoexpression in cervical cancer. Eur J Gynaecol
Oncol. 2010;31(4):380-5.
69. Thangavelu PU, Krenács T, Dray E, Duijf PH. In epithelial cancers,
aberrant COL17A1 promoter methylation predicts its misexpression and
increased invasion. Clin Epigenetics. 2016;8:120, http://dx.doi.org/10.1186/
s13148-016-0290-6.
70. Numa F, Hirabayashi K, Kawasaki K, Sakaguchi Y, Sugino N, Suehiro Y,
et al. Syndecan-1 expression in cancer of the uterine cervix: association
with lymph node metastasis. Int J Oncol. 2002;20(1):39-43.
71. Shinyo Y, Kodama J, Hasengaowa, Kusumoto T, Hiramatsu Y. Loss of
cell-surface heparan sulfate expression in both cervical intraepithelial
neoplasm and invasive cervical cancer. Gynecol Oncol. 2005;96(3):776-83,
http://dx.doi.org/10.1016/j.ygyno.2004.11.004.
72. Kim YI, Lee A, Lee BH, Kim SY. Prognostic significance of syndecan-1
expression in cervical cancers. J Gynecol Oncol. 2011;22(3):161-7, http://
dx.doi.org/10.3802/jgo.2011.22.3.161.
73. Sobel G, Páska C, Szabó I, Kiss A, Kádár A, Schaff Z. Increased expression of
claudins in cervical squamous intraepithelial neoplasia and invasive carcinoma.
Hum Pathol. 2005;36(2):162-9, http://dx.doi.org/10.1016/j.humpath.2004.12.001.
74. al-Saleh W, Delvenne P, van den Brule FA, Menard S, Boniver J,
Castronovo V. Expression of the 67 KD laminin receptor in human cervical
preneoplastic and neoplastic squamous epithelial lesions: an immunohisto-
chemical study. J Pathol.1997;181(3):287-93, http://dx.doi.org/10.1002/
(SICI)1096-9896(199703)181:3o287::AID-PATH76243.0.CO;2-W.
75. Gorter A, Zijlmans HJ, van Gent H, Trimbos JB, Fleuren GJ, Jordanova ES.
Versican expression is associated with tumor-infiltrating CD8-positive
T cells and infiltration depth in cervical cancer. Mod Pathol. 2010;23(12):
1605-15, http://dx.doi.org/10.1038/modpathol.2010.154.
76. Kohrenhagen N, Volker HU, Kapp M, Dietl J, Kammerer U. Increased
expression of galectin-1 during the progression of cervical neoplasia. Int J
Gynecol Cancer. 2006;16(6):2018-22, http://dx.doi.org/10.1111/j.1525-
1438.2006.00741.x.
77. Huang EY, Chanchien CC, Lin H, Wang CC, Wang CJ, Huang CC.
Galectin-1 is an independent prognostic factor for local recurrence and
survival after definitive radiation therapy for patients with squamous
cell carcinoma of the uterine cervix. Int J Radiat Oncol Biol Phys. 2013;
87(5):975-82, http://dx.doi.org/10.1016/j.ijrobp.2013.08.037.
78. Fullár A, Dudás J, Oláh L, Hollósi P, Papp Z, Sobel G, et al. Remodeling of
extracellular matrix by normal and tumor-associated fibroblasts promotes
cervical cancer progression. BMC Cancer. 2015;15:256, http://dx.doi.org/
10.1186/s12885-015-1272-3.
79. Füle T, Csapó Z, Máthé M, Tátrai P, László V, Papp Z, et al. Prognostic
significance of high-risk HPV status in advanced cervical cancers and
pelvic lymph nodes. Gynecol Oncol. 2006;100(3):570-8, http://dx.doi.
org/10.1016/j.ygyno.2005.09.019.
80. Karvinen S, Kosma VM, Tammi MI, Tammi R. Hyaluronan, CD44 and
versican in epidermal keratinocyte tumours. Br J Dermatol. 2003;148(1):
86-94, http://dx.doi.org/10.1046/j.1365-2133.2003.05028.x.
81. Hartmann-Petersen S, Tammi RH, Tammi MI, Kosma VM. Depletion
of cell surface CD44 in nonmelanoma skin tumours is associated with
increased expression of matrix metalloproteinase 7. Br J Dermatol. 2009;
160(6):1251-7, http://dx.doi.org/10.1111/j.1365-2133.2009.09031.x.
7
CLINICS 2018;73(suppl 1):e551s HPV and the extracellular matrix
Herbster S et al.
